The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.
Foundation Venture Capital Group (FVCG), the corporate venturing affiliate of New Jersey Health Foundation, has invested $100,000 in Actinobac Biomed. The portfolio company has exclusive rights to the therapeutic use of Leukothera, which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells, through a license from the University of Medicine and Dentistry of New Jersey.
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
